In this episode ofThe BioHub Podcast by Avetix, Ben sits down with Shawn Singh, CEO of Vistagen Therapeutics, to discuss his career across biotech, venture capital, CROs, public markets, and the evolution of neuropsychiatry drug development.With more than 30 years of experience spanning private and public biotechnology, medtech, pharma, venture capital, and contract research, Shawn brings a uniquely broad perspective on what it takes to build and lead companies through different stages of growth.In this conversation, Shawn shares reflections on the lessons learned from building and financing life sciences companies, leading through changing market cycles, and staying focused on long-term value creation in CNS. He also discusses Vistagen’s approach to developing differentiated treatments for anxiety, depression, and other neuropsychiatric disorders, the importance of patient need in shaping strategy, and what it takes to advance innovation in an area where new treatment options are urgently needed.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Episode 165 - Karen Lewis - CPO of Cardurion Pharmaceuticals
Episode 164 - Natalia Misciattelli - CEO of AAVantgarde
Episode 163 - Ken Macnamara - CEO at Trogenix
Episode 162 - Arun Swaminathan - CEO at Coya Therapeutics
Free AI-powered recaps of The BioHub - by Avetix and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.